United States Patent 12,594,243 Scope and Claims for Bexagliflozin Sustained-Exposure Tablet Formulation (80–150 ng/mL Fasted Cmax)
US 12,594,243 is a formulation-centric US patent that claims a specific bexagliflozin tablet composition, a dissolution/exposure performance window (fasted Cmax 80–150 ng/mL), and specific excipient subranges and amounts. Claim scope is tightly anchored to: (i) a defined binder-lipid-surfactant-polymer matrix (glyceryl dibehenate plus polyethylene oxide 900,000 plus poloxamer 188 plus lactose plus microcrystalline cellulose plus colloidal silicon dioxide plus magnesium stearate); (ii) a narrow bexagliflozin content range (with a dependent exemplar); and (iii) defined in vitro dissolution behavior under USP Apparatus 1 in 0.1 N HCl, with 3-hour and 5-hour release percentages. A film-coating composition is also claimed in dependent claims using polyvinyl alcohol, titanium dioxide, and polyethylene glycol 3350, with a further dependent claim adding specific colorants and a named polyanionic dye system.
The result is a patent estate that is likely to be highly valuable for licensing and for formulation design-around, because infringement is plausibly limited to products that meet both composition and performance criteria.
What does US Patent 12,594,243 claim for bexagliflozin tablets in the US?
Claim 1: composition + fasted plasma Cmax performance window
Claim 1 is the independent claim and defines a bexagliflozin tablet by both composition and pharmacokinetic performance:
Scope implication: To land within claim 1, an accused product must satisfy the excipient weight ranges and also hit the fasted Cmax window. That creates a dual infringement pathway: composition-based and exposure-based. If a generic changes composition but still achieves the Cmax window, claim 1 may still be in play only if the composition ranges are met. If a generic stays within composition but yields a different Cmax, claim 1 may be avoided.
Claim 2: narrows composition to mg ranges + same Cmax window
Claim 2 further defines the tablet by absolute mg ranges (rather than wt %), while retaining the 80–150 ng/mL fasted Cmax feature:
- (a) 3–60 mg bexagliflozin
- (b) 50–75 mg PEO (900,000 g/mol)
- (c) 100–140 mg glyceryl dibehenate
- (d) 40–50 mg lactose
- (e) 40–45 mg poloxamer 188
- (f) 60–80 mg microcrystalline cellulose
- (g) 4–5 mg colloidal silicon dioxide
- (h) 6–9 mg magnesium stearate
- PK: fasted Cmax 80–150 ng/mL
Scope implication: Claim 2 is likely the main target for infringement analysis because it is closer to a “formulation recipe” with testable tablet-level quantities.
Claim 3: fully exemplified “20 mg” embodiment
Claim 3 depends from claim 2 and locks into a specific set of amounts:
- 20 mg bexagliflozin
- 65 mg PEO (900,000)
- 120 mg glyceryl dibehenate
- 45 mg spray-dried lactose monohydrate
- 42 mg micronized poloxamer 188
- 70 mg microcrystalline cellulose
- 4.5 mg amorphous anhydrous colloidal silicon dioxide
- 7.5 mg magnesium stearate
Scope implication: This claim is narrower than claim 2 but provides a clean infringement hook for products that replicate the exemplar.
Claim 4: film coating composition (PVA + TiO2 + PEG 3350)
Claim 4 adds a coating in a dependent manner:
- Film coating comprising polyvinyl alcohol, titanium dioxide, and polyethylene glycol 3350.
Scope implication: A defendant changing film composition could attempt to avoid claim 4 while still infringing earlier composition claims. Whether coating becomes relevant depends on whether the coating is required for infringement or only as an additional feature for a dependent claim.
Claim 5: specific coating mixture with dyes
Claim 5 depends from claim 3 and recites a coating “consisting of” 11.22 mg of a defined mixture including:
- polyvinyl alcohol, titanium dioxide, polyethylene glycol 3350, talc
- disodium 2-[[4-[ethyl-[(3-sulfonatophenyl)methyl]amino]phenyl]-[4-[ethyl-[3-sulfonatophenyl)methyl]azaniumylidene]cyclohexa-2,5-dien-1-ylidene]methyl]benzenesulfonate
- indigo carmine
Scope implication: “Consisting of” narrows this claim. Most competitors using different colorants or coating composition would likely steer outside claim 5.
Claims 6 and 7: dissolution release ranges in 0.1 N HCl using USP Apparatus 1
Claim 6:
- Releases 20–45% by weight of bexagliflozin after 3 hours
- USP Apparatus 1, 50 rpm, 900 mL 0.1 N HCl, 37±0.5°C.
Claim 7:
- Releases 45–75% by weight after 5 hours with the same test method.
Scope implication: These create a performance fence. Even if a product fits the excipient composition, failure to match the dissolution release windows creates a credible design-around.
What are the critical claim elements and how do they constrain infringement?
1) Excipient identity and parameterization
The claims are not “any sustained release bexagliflozin tablet.” They demand:
- PEO with avg MW 900,000 g/mol
- glyceryl dibehenate at very high levels (30–35 wt %; 100–140 mg in claim 2)
- poloxamer 188 at 10–12 wt % or 40–45 mg
- fixed inclusion of lactose, microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate
2) Exposure constraint: fasted Cmax 80–150 ng/mL
Claim 1 and claim 2 require that the tablet achieves a fasted Cmax in a human range.
- This is often a litigation focal point because Cmax is affected by manufacturing, particle size, solid-state properties, and dissolution behavior.
- It is also a potential proof-of-infringement lever for the patentee (clinical or bioequivalence-type data).
3) Dissolution performance
Claims 6 and 7 specify in vitro release under a specific compendial method in 0.1 N HCl.
- A product can avoid those dependent claims by shifting release profile out of the ranges.
- But if the product is used to satisfy or evade claim 1/2 exposure bounds, it will also influence whether the fasted Cmax lands within 80–150 ng/mL.
How strong is the patent estate for formulation IP around US 12,594,243?
Inherent enforceability strengths (based on claim drafting)
- Tight excipient matrix: high-level quantitative ranges for multiple components reduce “partial design-around” options.
- PK + dissolution fences: dependent claims add separate testable features.
- “Consisting of” language in coating: claim 5 is narrow and can be asserted selectively.
Enforceability vulnerabilities (based on claim drafting)
-
The presence of multiple ranges creates both opportunity and ambiguity for non-literal design-around, particularly if a competitor shifts:
- PEO molecular weight away from 900,000 (even if using a close polymer),
- glyceryl dibehenate content,
- poloxamer class or type,
- the lactose form,
- release kinetics to move Cmax outside 80–150 ng/mL.
-
If a competitor’s product sits near boundaries, infringement arguments may center on assay variability, lot-to-lot performance, and test conditions.
What formulations are protected by US 12,594,243?
Core protected formulation “themes”
- A high glyceryl dibehenate content matrix (a lipid-like or hydrophobic component)
- A high-MW PEO (900,000) polymer providing hydrophilic gel/erosion behavior
- Poloxamer 188 as a surfactant/tuning excipient
- Powdered flow and disintegration support via lactose + MCC
- Physical stabilization via colloidal silicon dioxide + magnesium stearate
- Optional film coating composition claims that are narrower and depend on the embodiment
Protected dosage scale
- Claim 2 covers 3–60 mg bexagliflozin tablets with corresponding excipient mg ranges.
- Claim 3 provides a specific 20 mg embodiment.
Which competitors face generic entry risk under this patent?
No company identification, product names, or Orange Book listings are provided in the prompt; therefore, a company-level or paragraph IV–style landscape cannot be constructed from the information given.
When does US 12,594,243 expire and how does exclusivity timing work?
No filing, priority, patent term adjustment, or maintenance status inputs are provided. A precise exclusivity/expiration timeline cannot be produced from the claim text alone.
What patent design-around strategies are suggested by the claim boundaries?
1) Move out of excipient identity or parameter
- Use a different polymer grade than PEO avg MW 900,000 g/mol.
- Replace glyceryl dibehenate with an alternate lipid in sustained release systems (even if chemically similar).
- Replace poloxamer 188 with a different poloxamer or non-poloxamer surfactant system.
2) Keep composition but shift performance
- Adjust formulation processing or excipient grades so fasted Cmax shifts outside 80–150 ng/mL.
- Adjust release so the product misses:
- 20–45% at 3 hours
- 45–75% at 5 hours
under the specified USP Apparatus 1 test conditions.
3) Change film coating
- Alter colorant package and coating recipe to avoid claim 4/5 dependent features.
- Use a coating that does not match PVA + TiO2 + PEG 3350 system or avoids the specific “consisting of” mixture in claim 5.
Detailed claim chart for US 12,594,243 (element-by-element)
| Claim |
Element type |
Limitation |
Litigation relevance |
| 1 |
Composition (wt %) |
Bexagliflozin 1–13% |
Literal infringement gate |
| 1 |
Composition (wt %) |
Glyceryl dibehenate 30–35% |
High-impact range |
| 1 |
Composition (wt %) |
PEO avg MW 900,000: 16–20% |
High-specificity |
| 1 |
Composition (wt %) |
Lactose 11–13% |
Ingredient-specific |
| 1 |
Composition (wt %) |
Poloxamer 188 10–12% |
Ingredient-specific |
| 1 |
Composition (wt %) |
MCC 18–20% |
Ingredient-specific |
| 1 |
Composition (wt %) |
Colloidal SiO2 1.0–1.5% |
Ingredient-specific |
| 1 |
Composition (wt %) |
Mg stearate 1.5–2.5% |
Ingredient-specific |
| 1 |
Performance (PK) |
Fasted Cmax 80–150 ng/mL |
Central proof point |
| 2 |
Composition (mg) |
Bexagliflozin 3–60 mg |
Literal infringement gate |
| 2 |
Composition (mg) |
PEO 900,000: 50–75 mg |
High-specificity |
| 2 |
Composition (mg) |
Glyceryl dibehenate 100–140 mg |
High-impact range |
| 2 |
Composition (mg) |
Lactose 40–50 mg |
Ingredient-specific |
| 2 |
Composition (mg) |
Poloxamer 188 40–45 mg |
Ingredient-specific |
| 2 |
Composition (mg) |
MCC 60–80 mg |
Ingredient-specific |
| 2 |
Composition (mg) |
Colloidal SiO2 4–5 mg |
Ingredient-specific |
| 2 |
Composition (mg) |
Mg stearate 6–9 mg |
Ingredient-specific |
| 2 |
Performance (PK) |
Fasted Cmax 80–150 ng/mL |
Central proof point |
| 3 |
Exemplar amounts |
20 mg bexagliflozin; 65 mg PEO; 120 mg glyceryl dibehenate; etc. |
Narrow embodiment |
| 4 |
Coating |
Film coating includes PVA + TiO2 + PEG 3350 |
Dependent; design-around possible |
| 5 |
Coating |
“Consisting of” 11.22 mg mixture incl. listed dyes |
Narrow dependent |
| 6 |
Dissolution |
20–45% release at 3 hours; USP 1, 50 rpm, 900 mL 0.1N HCl |
Dependent performance claim |
| 7 |
Dissolution |
45–75% release at 5 hours; same test |
Dependent performance claim |
Key Takeaways
- US 12,594,243 is a tablet formulation patent that ties infringement to a defined bexagliflozin matrix using glyceryl dibehenate + PEO (900,000) + poloxamer 188 + lactose + MCC plus specific auxiliaries.
- The patent adds a fasted Cmax performance window of 80–150 ng/mL, creating a combined composition-and-performance infringement model.
- Dependent claims tighten enforceability via:
- a defined film coating system (PVA/TiO2/PEG 3350) and a narrow dye-containing “consisting of” coating package, and
- USP Apparatus 1 dissolution release windows at 3 and 5 hours in 0.1 N HCl.
- Practical design-around levers implied by claim boundaries are: polymer grade, glyceryl dibehenate level, poloxamer selection, and shifting fasted Cmax and dissolution release out of the claimed ranges.
FAQs
1) What part of US 12,594,243 is most likely to be litigated, composition or fasted Cmax?
The independent claims (1 and 2) require both the excipient composition ranges and the fasted Cmax of 80–150 ng/mL, so both are central. Performance evidence will be needed to connect formulation to exposure.
2) Does US 12,594,243 protect any bexagliflozin sustained-release tablet or only one with the specific excipient matrix?
Only tablets meeting the recited excipient identities and quantitative ranges, plus the fasted Cmax window, are covered by claim 1 and claim 2.
3) If a product matches the excipient percentages but misses the dissolution profile, does it avoid claims 6 and 7?
Yes. Claims 6 and 7 are dependent and require specific release percentages at 3 and 5 hours under the specified USP 1 conditions.
4) Can a generic avoid coating-dependent claims (4 and 5) while still infringing earlier claims?
Yes. Claims 4 and 5 add coating features in dependent form. Avoiding those coating limitations does not automatically escape claim 1 or claim 2 if the core tablet composition and fasted Cmax are met.
5) What manufacturing or formulation changes are most effective based on these claim ranges?
Changing the PEO molecular weight grade away from 900,000, substituting glyceryl dibehenate or altering poloxamer 188 content, and engineering the product so fasted Cmax and USP 1 dissolution release fall outside the claimed windows.
References (APA)
- United States Patent Application/Patent No. 12,594,243 (claims as provided).
